These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

472 related items for PubMed ID: 11753448

  • 1. [Multicenter study in southern South America of the in vitro activity of telithromycin in strains with defined resistance phenotypes isolated from community-acquired respiratory infections].
    Casellas JM, Visser M, Mac Dougall N, Coco B, Tomé G, Gliosca L, Grupo Colaborativo de Telitromicina del Cono Sur.
    Rev Esp Quimioter; 2001 Sep; 14(3):269-74. PubMed ID: 11753448
    [Abstract] [Full Text] [Related]

  • 2. Activities of 16-membered ring macrolides and telithromycin against different genotypes of erythromycin-susceptible and erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae.
    Mazzariol A, Koncan R, Vitali LA, Cornaglia G.
    J Antimicrob Chemother; 2007 Jun; 59(6):1171-6. PubMed ID: 17405779
    [Abstract] [Full Text] [Related]

  • 3. Comparative activity of telithromycin against typical community-acquired respiratory pathogens.
    Buxbaum A, Forsthuber S, Graninger W, Georgopoulos A.
    J Antimicrob Chemother; 2003 Sep; 52(3):371-4. PubMed ID: 12888585
    [Abstract] [Full Text] [Related]

  • 4. Comparative in vitro activity of telithromycin against macrolide-resistant and -susceptible Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae.
    Walsh F, Carnegy F, Willcock J, Amyes S.
    J Antimicrob Chemother; 2004 May; 53(5):793-6. PubMed ID: 15056640
    [Abstract] [Full Text] [Related]

  • 5. Antibacterial resistance of community-acquired respiratory tract pathogens recovered from patients in Latin America: results from the PROTEKT surveillance study (1999-2000).
    Mendes C, Marin ME, Quiñones F, Sifuentes-Osornio J, Siller CC, Castanheira M, Zoccoli CM, López H, Súcari A, Rossi F, Angulo GB, Segura AJ, Starling C, Mimica I, Felmingham D.
    Braz J Infect Dis; 2003 Feb; 7(1):44-61. PubMed ID: 12807691
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Telithromycin: the first ketolide antibacterial for the treatment of community-acquired respiratory tract infections.
    Lorenz J.
    Int J Clin Pract; 2003 Feb; 57(6):519-29. PubMed ID: 12918892
    [Abstract] [Full Text] [Related]

  • 19. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01.
    Doern GV, Brown SD.
    J Infect; 2004 Jan; 48(1):56-65. PubMed ID: 14667792
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.